Dr. Jinguan Lin 林劲冠
Chief Physician
Department of Radiation Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lung cancer, breast cancer, malignant lymphoma, and gastrointestinal tumors.
Dr. Lin is a Chief Physician and Center Director at Hunan Cancer Hospital. After graduating from Hunan Medical University, Dr. Lin has worked in clinical oncology. Dr. Lin manages multiple clinical trials for new drugs and has published nearly ten papers in domestic core journals, including one that received a first-prize award from the Chinese Society of Clinical Oncology (CSCO).
Name order: in Chinese the family name comes first (Lin Jinguan). Papers usually list the name as Jinguan Lin or Lin J.
Selected publications
51 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Med, 2026 (first author): Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. PubMed 42706605
- Cancer Lett, 2025 (first author): Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody. PubMed 39892704
- Oral Oncol, 2023 (senior author): Application of sovantinib in large cell neuroendocrine carcinoma of tonsil: A case report and literature review. PubMed 37011427
- Front Immunol, 2022 (senior author): Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer. PubMed 36119046
- Oncogene, 2022 (first author): The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity. PubMed 34997215
- J Exp Clin Cancer Res, 2019 (first author): The roles of glucose metabolic reprogramming in chemo- and radio-resistance. PubMed 31122265
- Exp Ther Med, 2019 (senior author): Anti-bacterial activity of mutant chensinin-1 peptide against multidrug-resistant Pseudomonas aeruginosa and its effects on biofilm-associated gene expression. PubMed 30867692
- Biomed Pharmacother, 2018 (first author): LncRNA HIF1A-AS2 positively affects the progression and EMT formation of colorectal cancer through regulating miR-129-5p and DNMT3A. PubMed 29278853
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion